JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022
CEO Raman Singh speaks about his mission to bring accessibility to the core of pharmaceutical innovation while being committed to ESG.
Juniper Biologics Establishes Global Headquarters in Singapore
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis
Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive